NSE · IPCALAB.NS
Ipca Laboratories Limited
₹1,930.00+₹3.80 (+0.2%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.3% below the high.
Loading market information…
NSE · SOLARA.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Solara Active Pharma Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 17.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Solara Active Pharma Sciences Limited’s forward annual dividend is ₹16.00 per share, paid quarterly. The forward yield is 2.51% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Solara Active Pharma Sciences Limited’s next earnings report is currently expected on Feb 11, 2027, with estimated earnings per share of ₹14.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Solara Active Pharma Sciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 15, 2025 | -₹0.54 | ₹2.73B-37.7% vs estimate |
|---|
| Q3 2025 | Jan 24, 2025 | ₹2.03 | ₹3.00B-21.11% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,930.00+₹3.80 (+0.2%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.3% below the high.
₹845.55+₹8.20 (+0.98%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.49% below the high.
₹939.10+₹3.50 (+0.37%)
Shilpa Medicare Limited’s quoted price sits in the upper half of its reported 52-week range, 14.24% below the high.
₹1,433.60+₹36.20 (+2.59%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.36% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹179.24-₹5.69 (-3.08%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 19.98% below the high.
₹508.45+₹22.65 (+4.66%)
SMS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 3.15% below the high.
₹854.65-₹38.75 (-4.34%)
Orchid Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 25.26% below the high.
